PRCT (PROCEPT BioRobotics) Growth Rank: 10 (As of Jul. 13, 2026) — Near Median


PRCT PROCEPT BioRobotics Corp PRCT
70 GF Score
Price $21.33
GF Value $93.20
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is PROCEPT BioRobotics Growth Rank?

PROCEPT BioRobotics PRCT +2.06% 70 Growth Rank is 10 as of Jul. 13, 2026, which is at its 10-year median of 10.00. GuruFocus rates PRCT with a GF Score™ of 70/100 and a GF Value™ of $93.20 (Significantly Undervalued). The stock has 2 warning signs investors should review.

PROCEPT BioRobotics has the Growth Rank of 10.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

PROCEPT BioRobotics Growth Rank Related Terms

PRCT vs ENOV, INSP, IRMD: Growth Rank Comparison

For the Medical Devices subindustry, PROCEPT BioRobotics's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PROCEPT BioRobotics Growth Rank vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, PROCEPT BioRobotics's Growth Rank distribution charts can be found below:

* The bar in red indicates where PROCEPT BioRobotics's Growth Rank falls into.


PRCT
70GF Score
PROCEPT BioRobotics Corp PRCT
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 10 mean?
PROCEPT BioRobotics (PRCT) has a Growth Rank of 10 as of Jul. 13, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on PROCEPT BioRobotics and its competitors. This is near median its historical median of 10.00. Over the past decade, PROCEPT BioRobotics' Growth Rank has ranged from 10.00 to 10.00.
Is PROCEPT BioRobotics' Growth Rank too high?
PROCEPT BioRobotics' current Growth Rank of 10 is near median its 10-year median of 10.00. Over the past 10 years, this metric has ranged from a low of 10.00 to a high of 10.00. Overall, PROCEPT BioRobotics has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PROCEPT BioRobotics' Growth Rank compare to ENOV and INSP?
PROCEPT BioRobotics' Growth Rank of 10 can be compared against companies in the Medical Devices & Instruments industry. Historically, PROCEPT BioRobotics' own Growth Rank has ranged from 10.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Medical Devices & Instruments company?
A good Growth Rank depends on the Medical Devices & Instruments industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on PROCEPT BioRobotics and its competitors. PROCEPT BioRobotics's current Growth Rank is 10, which is near median its own 10-year median of 10.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PROCEPT BioRobotics stock overvalued right now?
Based on GuruFocus' analysis, PROCEPT BioRobotics (PRCT) is currently considered Significantly Undervalued. The stock's GF Value™ is $93.20, compared to a current price of $21.33 — trading 77.1% below its estimated fair value. The current Growth Rank is 10, which is near median its 10-year median of 10.00. PROCEPT BioRobotics' overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For PROCEPT BioRobotics (PRCT), the current Growth Rank is 10 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PROCEPT BioRobotics (PRCT) Overvalued in 2026?

Based on GuruFocus' analysis, PROCEPT BioRobotics stock appears to be undervalued. The current stock price of $21.33 is trading 77.1% below its estimated GF Value™ of $93.20. GuruFocus considers PROCEPT BioRobotics to be Significantly Undervalued.

Key valuation signals for PRCT:

  • Growth Rank: 10 (near median its 10-year median of 10.00)
  • GF Value™: $93.20 vs. price of $21.33 (77.1% below fair value)
  • GF Score™: 70/100 with 2 warning signs

No single metric tells the full story. See the PRCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PROCEPT BioRobotics Business Description

Other Exchanges PRCT:Mexico
Address 150 Baytech Drive, San Jose, CA, USA, 95134
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
70GF Score

Get the complete analysis for PRCT

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.33
Price
$93.20
GF Value